Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$63,483.00-0.06%ETH$1,886.42+0.31%GOLD$4,396.70-0.54%OIL$81.15-0.12%
Smart Investors Daily
Sign InSign Up Free
AD

NASDAQ · ADGI

Adagio Therapeutics, Inc.

Healthcare · Biotechnology

$4.64

Up+$0.04 (+0.87%)

Updated Aug 14, 2026, 2:09 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
505.68M
P/E ratio
-4.8
Dividend yield
0.00%
52-week range
— – —
Volume
535K
Avg. volume
658.59K

Price performance

ADGI price history

1M range · 0 trading sessions · Daily adjusted prices

ADGI does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ADGI news

The latest Smart Investors Daily articles mentioning ADGI.

Stock researchCompany · Overview

ADGI research

Overview

Company profile and research snapshot.

Company profile

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ADGI recent ratings
DateFirmRatingTarget
May 17, 2022Morgan StanleyUnderweight—
Jan 6, 2022Morgan StanleyUnderweight—
Dec 22, 2021JefferiesHold—
Dec 15, 2021GuggenheimNeutral—
Dec 15, 2021Morgan StanleyEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Sep 12, 2022

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD beginning September 13), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, announced today that the Company has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD200. NVD200 is expected to enter the clinic in the first quarter of 2023.

GlobeNewswire Inc. · Jul 5, 2022

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced today that industry and infectious disease veteran David Hering, who has been serving as the company’s interim chief executive officer and chief operating officer, has been named permanent CEO and a director on the company’s Board of Directors.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By